---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000659"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T20:52:11.187017+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunic reports phase 1b IMU-856 data: reduced villous height loss, improved symptoms, no safety issues

## Summary
- Placebo group had 60.3 µm villous height reduction vs. 20.9 µm (80mg) and 22.5 µm (160mg) for IMU-856 (p=0.04) under gluten challenge.
- On first gluten challenge day, placebo symptom increases (nausea 0.8, pain 0.8, diarrhea 0.8) vs. pooled IMU-856 (0.4, 0.5, 0.6) on 5-point scale.
- Dose-dependent lessening of serum IL-2 release with IMU-856; citrulline levels increased in active arms while decreasing in placebo.
- Vitamin B12 increased by 45.8 pmol/L (80mg) and 74.2 pmol/L (160mg) with IMU-856 vs. 31.0 pmol/L decrease with placebo.
- No serious adverse events; two IMU-856 patients showed Q-Marsh histology improvement despite gluten challenge vs. none on placebo.

## SEC filing metadata
- accession: 0001193805-23-000659
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000659/0001193805-23-000659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380523000659/e618584_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000659
- JSON: https://secwatch.observer/filing/0001193805-23-000659.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.